CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Tocilizumab 180 MG/MLWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1485 Methylprednisolone Sodium Succinate Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial

This study compare the efficacy and safety of tocilizumab versus methylprednisolone in the cytokine release syndrome of patients with COVID-19

NCT04377503 Cytokine Release Syndrome Covid-19 Drug: Tocilizumab 180 MG/ML Drug: Methylprednisolone Sodium Succinate
MeSH:Syndrome

Primary Outcomes

Description: A seven-category ordinal scale consisting of: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.

Measure: Patient clinical status 15 days after randomization

Time: 15 days after randomization

Secondary Outcomes

Description: Improvement in PaO2/FIO2

Measure: Improving oxygenation

Time: 15 days

Description: Improvement in the computed tomography between D0 and D10 after randomization

Measure: Thorax CT improvement

Time: 10 days

Description: Duration o ICU stay in days

Measure: ICU length of stay

Time: 28 days

Description: Days of mechanical ventilation

Measure: Duration of mechanical ventilation

Time: 28 days

Description: AKI according to Kidney Disease Improving Global Outcomes (KDIGO)

Measure: Incidence of acute kidney (AKI) with necessity of renal replacement therapy

Time: 15 days

No related HPO nodes (Using clinical trials)